Study of SHR-1210 Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal Cancer
Status:
Completed
Trial end date:
2019-05-06
Target enrollment:
Participant gender:
Summary
In this study, participants with advanced or metastatic squamous cell carcinoma of the
esophagus that has progressed after first-line standard therapy will be randomized to receive
either single agent SHR-1210 or the Investigator's choice of standard therapy with docetaxel
or irinotecan. The primary study hypothesis is that treatment with SHR-1210 will prolong
overall survival (OS) as compared to treatment with standard therapy.